Overview

Long-Term Safety Study of BHV3000 for the Acute Treatment of Migraine in Chinese Subjects

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
Phase:
Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.
Collaborator:
Bioshin (Shanghai) Consulting Services Co., Ltd